232 related articles for article (PubMed ID: 4695960)
1. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
Cruse JM; Whitten HD; Lewis GK; Watson ES
Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
[No Abstract] [Full Text] [Related]
2. Antigen driven selection for Fc receptors of enhancing antibody on macrophages during an alloimmune response.
Whitten HD; Cruse JM; Lewis GK; Watson ES
J Reticuloendothel Soc; 1974 Feb; 15(2):118-25. PubMed ID: 4815211
[No Abstract] [Full Text] [Related]
3. Effects of tumor-enhancing IgG2 on macrophage function.
Cruse JM; Lewis R; Dilioglou S
Exp Mol Pathol; 2004 Aug; 77(1):43-8. PubMed ID: 15215049
[TBL] [Abstract][Full Text] [Related]
4. Immunologic enhancement induced by antibody fragments.
Cruse JM; Forbes JT; Gillespie GY; Lewis GK
Z Immunitatsforsch Allerg Klin Immunol; 1970; 140(3):259-67. PubMed ID: 4251393
[No Abstract] [Full Text] [Related]
5. Modulation of the immune response to transplantation antigens. V. A comparison of the effects of antilymphocytic serum and enhancing alloantiserum on effector mechanisms of allograft rejection.
Zola H
Clin Exp Immunol; 1975 Feb; 19(2):367-76. PubMed ID: 1212805
[TBL] [Abstract][Full Text] [Related]
6. Transplantability and antigenicity of two sublines of the TA3 tumor.
Sanford BH; Codington JF; Jeanloz RW; Palmer PD
J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
[No Abstract] [Full Text] [Related]
7. Abrogation of tumor rejection by trypan blue.
Kreider JW; Bartlett GL; DeFreitas E
Cancer Res; 1978 Apr; 38(4):1036-40. PubMed ID: 205342
[TBL] [Abstract][Full Text] [Related]
8. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
9. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
Fogler WE; Fidler IJ
Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes.
Rouse BT; Wagner H; Harris AW
J Immunol; 1972 May; 108(5):1353-61. PubMed ID: 4623947
[No Abstract] [Full Text] [Related]
11. Tumor suppression by pyran copolymer: correlation with production of cytotoxic macrophages.
Harmel RP; zbar B
J Natl Cancer Inst; 1975 Apr; 54(4):989-92. PubMed ID: 1127729
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and enhancement of normal and tumor tissue in the mouse.
McKenzie IF; Snell GD
Transplant Proc; 1973 Mar; 5(1):953-6. PubMed ID: 4572155
[No Abstract] [Full Text] [Related]
13. Relationships among differentiated T-cell subpopulations. IV. Preferential induction of delayed footpad reaction to xenografts and its radioresistant nature.
Terasaka R; Nomoto K; Himeno K; Takeya T
Immunology; 1979 Apr; 36(4):699-705. PubMed ID: 312268
[TBL] [Abstract][Full Text] [Related]
14. Fate of murine fibrosarcoma allografts and radiolabeled tumor-enhancing IgG2, normal (nonenhancing) IgG2 and bacterial endotoxin in endotoxin-tolerant and nontolerant mice.
Cruse JM; Lewis GK; Whitten HD; Watson ES; Fields JF; Adams ST; Harvey GF; Paslay JW; Baldwin J; Porter M
J Reticuloendothel Soc; 1974 Jan; 15(1):75-84. PubMed ID: 4810604
[No Abstract] [Full Text] [Related]
15. Secondary cytotoxic tumor immune response induced in vitro.
Röllinghoff M
J Immunol; 1974 May; 112(5):1718-25. PubMed ID: 4544796
[No Abstract] [Full Text] [Related]
16. Specificity of immune paralysis at large tumor volumes.
Pardridge DH; Wang BS; Mannick JA; Deckers PJ
Surg Forum; 1975; 26():118-20. PubMed ID: 56046
[No Abstract] [Full Text] [Related]
17. [Serum factors that inhibit in vitro immunological reactions in malignant tumor development in experimental animals].
Lomakin MS; Larin AS; Mamaeva TN; Levitina VL
Vopr Onkol; 1977; 23(10):76-82. PubMed ID: 202095
[TBL] [Abstract][Full Text] [Related]
18. Protective serum effects in tumor immunity.
Vaage J
Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
[TBL] [Abstract][Full Text] [Related]
19. In vitro demonstration of tumor-specific common antigens and embryonal antigens in murine fibrosarcomas induced by 7,12-dimethylbenz(a)anthracene.
Ménard S; Colnaghi MI; Della Porta G
Cancer Res; 1973 Mar; 33(3):478-81. PubMed ID: 4689897
[No Abstract] [Full Text] [Related]
20. [Cytotoxic lymphocytes and anti-tumor immunity].
Cerottini JC; Brunner KT
Ann Inst Pasteur (Paris); 1972 Apr; 122(4):659-68. PubMed ID: 4403239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
